MedTrace Logo

Thiamine as a Metabolic Resuscitator After Cardiac Arrest

NCT03450707 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2023-08-24

Study results available
· View outcomes & findings →

Summary

This is a randomized, double-blind, placebo controlled study to investigate the effect of intravenous thiamine (vitamin B1) on lactate, cellular oxygen consumption, global oxygen consumption and biomarkers of neurologic injury after out-of-hospital cardiac arrest (OHCA). .

Conditions

  • Cardiac Arrest

Interventions

DRUG

Thiamine 500 mg IV

Thiamine hydrochloride (vitamin B1) 500mg IV will be given every 12 hours for 5 doses in the experimental arm.

OTHER

Placebo

100mL of intravenous normal saline will be given every 12hours for 5 doses in the placebo arm

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Michael Donnino

    lead OTHER

Principal Investigators

  • Michael W Donnino, MD · Beth Israel Deaconess Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-06
Primary Completion
2022-02-19
Completion
2022-02-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03450707 on ClinicalTrials.gov